Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

genome-targeted therapy, eligibility, response

Recent studies have been conducted to update the estimates of eligibility and response rates to genome-targeted therapies among US cancer patients, reflecting data up to 2020. The number of FDA-approved drugs targeting genetic indications has increased significantly since prior assessments. …

Apr 20^th • 7 mins read